What Evidence Can and Cannot Show About Tysabri and PML
From General Health Information to Targeted Risk Assessment
If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page presents what clinical evidence and prescribing information can—and cannot—tell us about that risk. Building on decades of pharmacovigilance research, we break down the FDA warnings, risk factors, and monitoring protocols so you can have an informed discussion with your healthcare provider.
Tysabri and PML: Medical Evidence and Risk Factors
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs in patients who are immunocompromised, and three factors are known to increase the risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered in the context of expected benefit when initiating and continuing treatment. The clinical presentation of PML is variable but typically includes subacute onset of neurologic deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid by polymerase chain reaction. Because PML can progress rapidly, the prescribing information instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers to evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The program also mandates reporting of PML cases, hospitalizations due to opportunistic infections, and deaths to Biogen.
Mechanism of PML and Adverse Event Reports
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocyte migration across the blood-brain barrier, thereby reducing immune surveillance in the central nervous system. This immunosuppressive effect allows latent JCV, which is present in a majority of the population, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, have received Tysabri for more than two years, or have a history of prior immunosuppressant use. Adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) for Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), fall (7,939 reports), memory impairment (7,895 reports), asthenia (7,852 reports), malaise (7,319 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and depression (3,091 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not establish causation, they reflect the spectrum of neurologic and systemic symptoms that may be associated with Tysabri use and that could overlap with early PML manifestations.
Statute of Limitations for Tysabri PML Claims in Arizona
For patients in Arizona who have developed PML after Tysabri exposure, settlement considerations involve the adequacy of warnings provided by the manufacturer. The boxed warning clearly states the increased risk of PML and identifies the three known risk factors. However, questions may arise regarding whether prescribers and patients were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of early discontinuation if symptoms appear. The timeline between exposure and documented harm is critical: PML typically occurs after months to years of Tysabri treatment, with risk increasing after two years. Patients who developed PML after shorter durations may have had additional risk factors such as anti-JCV antibody positivity or prior immunosuppressant use. The statute of limitations for filing a Tysabri-related PML lawsuit in Arizona is governed by state law, which generally requires claims to be brought within two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be the date of diagnosis, which often occurs after MRI and CSF testing. Patients and their families should consult with legal counsel promptly to ensure compliance with applicable deadlines. Settlement amounts in PML cases can vary widely based on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a mandated monitoring program. Patients in Arizona who have suffered PML after Tysabri use should be aware of the statute of limitations and the importance of timely legal action. The evidence supports that the drug's labeling includes warnings about PML, but individual circumstances may affect the adequacy of those warnings and the potential for settlement.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for a Tysabri PML lawsuit in Arizona?
In Arizona, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this is typically the date of diagnosis. It is crucial to consult with an attorney promptly to ensure compliance.
What are the known risk factors for PML in Tysabri patients?
The three known risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.